Investor Relations

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them.

CR-000172

Investor Overview

Investor Overview

Corporate Profile

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

News Releases

Date Title and Summary Additional Formats
Toggle Summary Charles River Laboratories Schedules Second-Quarter 2020 Earnings Release and Conference Call
WILMINGTON, Mass. --(BUSINESS WIRE)--Jul. 14, 2020-- Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2020 financial results on Wednesday, August 5 th , before the market opens. A conference call has been scheduled to discuss this information on Wednesday,
View HTML
Toggle Summary HemaCare Adds GMPrimeTM Cryopreserved Leukopak to its GMP Product Portfolio
Simplify complex study logistics with GMP-compliant cryopreserved leukopak for the development and commercialization of cell and gene therapies LOS ANGELES --(BUSINESS WIRE)--Jun. 2, 2020-- HemaCare Corporation , a Charles River Laboratories International, Inc.
View HTML
Toggle Summary Charles River Laboratories to Participate in Jefferies and William Blair Conferences
WILMINGTON, Mass. --(BUSINESS WIRE)--Jun. 1, 2020-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will virtually present at the Jefferies Virtual Healthcare Conference on Tuesday, June 2 nd , at 10:00 a.m. ET , and at the William Blair 40 th Annual Growth Stock
View HTML
Toggle Summary Charles River Laboratories Announces First-Quarter 2020 Results
– First-Quarter Revenue of $707.1 Million – – First-Quarter GAAP Earnings per Share of $1.02 and Non-GAAP Earnings per Share of $1.84 – – Revises 2020 Guidance Due to COVID-19 Impact – WILMINGTON, Mass. --(BUSINESS WIRE)--May 7, 2020-- Charles River Laboratories International, Inc.
View HTML

Featured Report

2019 Annual Report (PDF)